Mounjaro (tirzepatide) is a once-weekly injectable medication approved by the FDA in May 2022 for type 2 diabetes management in adults. It works through a dual mechanism, activating both GIP and GLP-1 receptors, which sets it apart from single-agonist GLP-1 drugs like semaglutide. The same molecule is sold as Zepbound for chronic weight management in adults with obesity or overweight plus a weight-related condition.
Unlike insulin or infused biologics, Mounjaro is self-administered by patients at home and is therefore billed through the pharmacy benefit (Medicare Part D, commercial pharmacy benefit) rather than the medical benefit (Medicare Part B). It does not have a permanent HCPCS Level II J-code for Part B billing because CMS classifies it as a self-administered drug excluded from Part B coverage. This means pricing is set entirely by the retail and specialty pharmacy market rather than Medicare ASP quarterly pricing schedules.
The out-of-pocket cost without any assistance program is one of the highest of any commonly prescribed outpatient drug. At $1,069 to $1,112 per month, a full year of Mounjaro would cost $12,828 to $13,344 at list price. Most patients pay far less through employer insurance, the Lilly Savings Card, or the Lilly Cares Foundation. Patients who check their Medicaid income limits may qualify for near-zero copays through state Medicaid programs, which cover Mounjaro for type 2 diabetes in most states.
What Mounjaro Cost Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same mounjaro cost can cost many times more at a hospital than at your local pharmacy:
2026 Mounjaro Cost Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (retail cash price) | $1,069 - $1,112/month | 4-pen carton, any dose strength, no coupon or insurance |
| Pharmacy counter with GoodRx coupon | $987 - $1,096/month | Price varies by pharmacy chain and location |
| Lilly Savings Card (commercial insurance covers) | As low as $25/month | For commercially-insured patients; not valid for Medicare |
| Lilly Savings Card (commercial insurance does NOT cover) | $499/month | Bridge pricing for commercially-insured patients whose plan excludes Mounjaro |
| Medicare Part D (type 2 diabetes indication) | Varies by plan; $2,100 annual OOP cap | Covered for T2D if on formulary; not covered for weight loss alone |
| Medicaid | $1 - $4/prescription | Most states cover for type 2 diabetes; check your state formulary |
Retail prices verified via GoodRx data, April-May 2026. Lilly Savings Card terms valid through December 31, 2026. Medicare Part D OOP cap is $2,100 for 2026 per the Inflation Reduction Act.
Source: GoodRx 2026, Lilly Savings Card program terms, CMS IRA Part D OOP cap
Why Hospitals Charge So Much
Mounjaro is self-administered by patients at home, so inpatient billing of tirzepatide is uncommon but does occur during hospital stays for unrelated conditions when the patient needs to continue their medication. Unlike insulin (which has a permanent Part B J-code and quarterly CMS ASP pricing), Mounjaro has no permanent HCPCS J-code. Hospitals that bill it use unclassified drug code J3490, which requires manual pricing and written documentation of dosage. This creates significant variability in what hospitals charge.
Patients who see Mounjaro on an inpatient itemized bill should request the NDC (National Drug Code) and verify the units billed against the actual dose administered. Because J3490 is an unclassified code, there is no published government rate to compare against, which makes inpatient Mounjaro charges harder to dispute than drugs with set ASP rates. If the charge is notably higher than the retail list price of approximately $1,069 per month (or $267 per weekly dose), that difference warrants a formal billing review. Use the CoveredUSA Medical Bill Analyzer at /medical-bill-analyzer to flag and document the discrepancy.
For outpatient use, the higher cost concern is not hospital billing but rather insurance denial. Many commercial plans require prior authorization and step therapy (proving you tried an older medication first) before approving Mounjaro. Denials for weight loss indications are near-universal on Medicare. Patients facing denials for diabetes management should ask their prescriber to appeal with documentation of A1C levels and prior treatment history, as diabetes-indication denials have a meaningful reversal rate.
Patient Assistance Programs
Eli Lilly runs two cost-reduction programs for Mounjaro: a Savings Card for patients with commercial insurance (including those whose plan does not cover Mounjaro), and the Lilly Cares Foundation Patient Assistance Program for uninsured and underinsured patients who meet income requirements. Neither program is valid for Medicare or Medicaid beneficiaries.
Patient assistance programs for Mounjaro Cost| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Lilly Savings Card (commercial insurance covers Mounjaro) | As low as $25 for a 1- or 3-month supply; max savings $647/month | mounjaro.lilly.com/savings-resources |
| Lilly Savings Card (commercial insurance does NOT cover Mounjaro) | $499/month; max annual savings $8,411 | mounjaro.lilly.com/savings-resources |
| Lilly Cares Foundation Patient Assistance Program | Free medication for up to 12 months; income at or below 400% FPL | lillycares.com |
Lilly Savings Card is not valid for patients using Medicare, Medicaid, or any government-funded insurance. Lilly Cares PAP requires a completed application from both the patient and prescriber. Income limits reflect 2026 federal poverty level guidelines. To find additional programs, search NeedyMeds.org by drug name.
Source: Lilly Cares Foundation (lillycares.com), Mounjaro Savings Resources (mounjaro.lilly.com/savings-resources), NeedyMeds.org
Medicare Part D
Medicare Part D may cover Mounjaro when prescribed for type 2 diabetes if your specific plan's formulary includes it. Coverage for weight loss alone is not available under current Medicare rules, as anti-obesity medications have historically been excluded from Part D coverage unless they also treat another covered condition. Most plans that cover Mounjaro list it in a specialty tier with the highest cost-sharing, though the 2026 Part D annual out-of-pocket cap of $2,100 limits total yearly drug spending regardless of tier.
Medicare beneficiaries cannot use the Lilly Savings Card or any other manufacturer copay assistance program for Part D drugs under current federal rules. Low-income Medicare beneficiaries should apply for Extra Help (also called LIS), which can reduce Part D copays to $0 to $10 per prescription for qualifying individuals. Eligibility for Extra Help is separate from Medicaid eligibility; you can apply through Social Security at ssa.gov. If you are near the Medicaid income threshold, check current Medicaid income limits for your state.
Common Mounjaro Cost Billing Errors
Mounjaro billing errors occur most often at commercial insurance plans and in inpatient settings. These are the most common issues patients and providers encounter:
- Prior authorization denial coded as a pharmacy error when the actual problem is missing documentation of a type 2 diabetes diagnosis (ICD-10 E11.x) rather than an obesity-only diagnosis (ICD-10 E66.x)
- Inpatient billing using J3490 without the required manual pricing documentation, resulting in claim denial or an arbitrary facility markup with no government benchmark rate to dispute against
- Brand confusion: Mounjaro (tirzepatide, for type 2 diabetes) billed when the patient uses Zepbound (same molecule, for obesity); the NDC numbers differ and payers may deny the claim or pay at a different rate
- Savings Card rejected at the pharmacy because the patient is on Medicare Part D; manufacturer copay cards are prohibited for federally-funded plans and the claim will fail
- Dose strength mismatch: the prescription is written for 5 mg/0.5 mL but the pharmacy dispenses 2.5 mg/0.5 mL as a starter dose without updating the claim, creating a unit billing error
Frequently Asked Questions
How much does Mounjaro cost per month without insurance in 2026?
The retail list price for Mounjaro in 2026 is $1,069 to $1,112 per month for a 4-pen carton (one month of weekly injections). Price is the same regardless of dose strength, from 2.5 mg up to 15 mg. With a GoodRx coupon, the out-of-pocket cash price drops to approximately $987 to $1,096 depending on the pharmacy.
Is there a patient assistance program for Mounjaro if I have no insurance?
Yes. The Lilly Cares Foundation Patient Assistance Program provides Mounjaro at no cost to uninsured or underinsured patients whose household income is at or below 400% of the federal poverty level. Applications require completion by both the patient and their prescriber and are submitted through lillycares.com. Approval provides medication for up to 12 months, after which you can reapply.
What is the Lilly Savings Card and how does it work for Mounjaro?
The Lilly Savings Card reduces Mounjaro cost for patients with commercial drug insurance. If your plan covers Mounjaro, you can pay as little as $25 for a 1-month or 3-month supply, with maximum monthly savings of $647. If your plan does not cover Mounjaro, the card reduces cost to $499 per month with a maximum annual savings of $8,411. The card is not valid for Medicare, Medicaid, or other government-funded insurance. It is valid through December 31, 2026.
Does Medicare cover Mounjaro?
Medicare Part D may cover Mounjaro if it is on your specific plan's formulary and you have a type 2 diabetes diagnosis. Medicare does not cover Mounjaro prescribed solely for weight loss under current rules. When covered, Mounjaro typically falls in a specialty tier with high cost-sharing, but the 2026 Part D annual out-of-pocket cap of $2,100 limits total yearly spending. Medicare beneficiaries cannot use the Lilly Savings Card.
Is Mounjaro the same drug as Zepbound?
Yes. Mounjaro and Zepbound both contain tirzepatide at the same dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). The difference is the FDA-approved indication: Mounjaro is approved for type 2 diabetes management, while Zepbound is approved for chronic weight management in adults with obesity or overweight plus a weight-related condition. Insurers treat them differently because of these different indications.
Can I get Mounjaro for $25 without insurance?
No. The $25 Lilly Savings Card price requires commercial drug insurance that covers Mounjaro. Without any insurance, the Savings Card is not available. Uninsured patients can apply for the Lilly Cares Foundation PAP, which provides free medication at income at or below 400% FPL, or use GoodRx coupons to bring the cash price to approximately $987 to $1,096 per month.
Why does Mounjaro cost so much without insurance?
Mounjaro is a brand-name specialty drug with no generic or biosimilar available as of 2026. Eli Lilly sets the list price at $1,069 to $1,112 per month, which reflects R&D costs, specialty manufacturing, and the lack of market competition at this drug class. Unlike insulin, which has a federally negotiated Medicare Part B rate, Mounjaro is billed through the pharmacy benefit and is not subject to CMS quarterly ASP price limits.
What are the alternatives to Mounjaro that cost less?
The closest alternative is Zepbound single-dose vials available through LillyDirect for approximately $299 to $449 per month depending on dose, but that is the weight management branded version of the same molecule and may not be appropriate for patients prescribed specifically for type 2 diabetes. Other GLP-1 class drugs (semaglutide products such as Ozempic) have similar list prices. Older diabetes medications such as metformin, sulfonylureas, and DPP-4 inhibitors with generics available cost $10 to $80 per month and may control blood sugar effectively as initial or combination therapy.
